By Kevin E. Noonan — During oral argument before the Supreme Court on Monday in Amgen v. Sanofi, all three advocates (Jeff Lamken for Amgen, Paul Clement for Sanofi, and Colleen Sindzak for the United States) had reason to reference and discuss an amicus brief submitted on behalf of Nobel Prize-winning scientist Sir Gregory Winter and colleagues,* on the scientific questions raised in the case with regard to what is sufficient to satisfy the enablement requirement of 35 U.S.C. § 112(a). The brief first extols the success of antibody technology as treatments for auto-immune inflammatory diseases and cancer that "has…
